(1S,2R)-N1-tert-Butoxycarbonyl-N2-[(5-methyl-4,5, 6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine | 365996-31-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (1S,2R)-N1-tert-Butoxycarbonyl-N2-[(5-methyl-4,5, 6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine
• 英文别名: (1S,2R)-N1-tert-Butoxycarbonyl-N2-[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine；tert-butyl N-[(1S,2R)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]carbamate
• CAS: 365996-31-2
• 化学式: C₁₉H₃₀N₄O₃S
• 分子量: 394.538
• InChiKey: PZZFHLZEAXPIOC-OLZOCXBDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  112
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (1S,2R)-N1-tert-Butoxycarbonyl-N2-[(5-methyl-4,5, 6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine 在 盐酸 作用下， 以 乙醇 为溶剂， 以100%的产率得到(+/-)-cis-N-[(5-Methyl-4,5,6,7-tetrahydrothiazolo-[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine
  参考文献：
  名称：

  Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors

  摘要：

  This paper describes the synthesis of orally available potent fXa inhibitors 2 and 3 by modification of tile piperazine part of lead compound 1. Carbonyl derivative 3 showed potent fXa activity but not sulfonyl derivative 2. Among the compounds synthesized, cyclohexane derivatives 3g and 3h and cycloheptane derivative 3j had potent anticoagulant activity as well as anti-fXa activity. Synthetic Study of the optical isomers of 3g demonstrated that (-)-3g had more potent activity.(c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.068
• 作为产物：
  描述：

  N-((2S,1S)-2-羟基环己基)氨基甲酸叔丁酯 在 palladium on activated charcoal 吡啶 、 sodium azide 、 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (1S,2R)-N1-tert-Butoxycarbonyl-N2-[(5-methyl-4,5, 6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]-1,2-cyclohexanediamine
  参考文献：
  名称：

  Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors

  摘要：

  This paper describes the synthesis of orally available potent fXa inhibitors 2 and 3 by modification of tile piperazine part of lead compound 1. Carbonyl derivative 3 showed potent fXa activity but not sulfonyl derivative 2. Among the compounds synthesized, cyclohexane derivatives 3g and 3h and cycloheptane derivative 3j had potent anticoagulant activity as well as anti-fXa activity. Synthetic Study of the optical isomers of 3g demonstrated that (-)-3g had more potent activity.(c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.05.068

文献信息

• Ethylenediamine derivatives
  申请人：——

  公开号：US20040122063A1

  公开（公告）日：2004-06-24

  The invention relates a compound represented by the formula (1): Q 1 -Q 2 -C(═O)—N(R 1 )-Q 3 -N(R 2 )-T 1 -Q 4 ( 1 ) wherein R 1 and R 2 represent H or the like; Q 1 represents an aromatic ring, heterocyclic ring or the like; Q 2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q 3 represents a group 1 or the like, Q 4 represents an aromatic ring, heterocyclic ring or the like; and T 1 represents —CO— or —SO 2 —, and a medicine which comprises the compound and is useful for thrombosis and embolism.

  本发明涉及一种由式（1）表示的化合物：Q1-Q2-C(═O)—N(R1)-Q3-N(R2)-T1-Q4(1)，其中R1和R2代表H或类似物；Q1代表芳香环，杂环或类似物；Q2代表单键，芳香环，杂环或类似物；Q3代表群1或类似物，Q4代表芳香环，杂环或类似物；T1代表—CO—或—SO2—，以及包含该化合物并对治疗血栓和栓塞有用的药物。
• ETHYLENEDIAMINE DERIVATIVES
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP1270557B1

  公开（公告）日：2012-07-25
• Monoacylated 1,2-diaminocycloalkanes
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2431370B1

  公开（公告）日：2013-06-19
• US7192968B2
  申请人：——

  公开号：US7192968B2

  公开（公告）日：2007-03-20
• US7935824B2
  申请人：——

  公开号：US7935824B2

  公开（公告）日：2011-05-03